相关实验视频

Updated: May 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K

通过双重DNA向评估特拉佐化的致癌潜力:通过结构计算评估分子相互作用,结合机制和亲和力

Palak Sharma1, Shweta Singh2, Priyanka Gopi3

  • 1Department of Forensic Science, Mody University of Science and Technology, Lakshmangarh, Rajasthan 332311, India.

Journal of pharmaceutical and biomedical analysis
|April 29, 2025
PubMed
概括

抗抑郁药特拉佐化 (TRZ) 与DNA的小沟结合,导致结构变化,破坏序列识别. 这项研究使用光谱和仿真方法阐明了TRZ-DNA相互作用.

关键词:
这就是CT-DNA.合规分析 合规分析光光谱学 光光谱学分子动力学分子动力学特拉佐二化的使用方法

更多相关视频

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

2.6K
Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin10:05

Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC Crosslinking of Small Molecules to Isolate Chromatin

Published on: January 20, 2016

8.2K

相关概念视频

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
429
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.1K